MRC vs. NVS

Last updated Jun 4, 2026

MRC (MRC Global Inc.) and NVS (Novartis AG) are both stocks. MRC operates in Oil & Gas Equipment & Services (Energy), while NVS operates in Drug Manufacturers - General (Healthcare). At a 0.19 correlation, their price movements are largely independent.

Performance

MRC vs. NVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MRC Global Inc. (MRC) and Novartis AG (NVS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

MRC

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

NVS

• 1D: 0.13%
• 1M: -0.66%
• YTD: 7.37%
• 6M: 10.70%
• 1Y: 27.68%
• 3Y*: 17.23%
• 5Y*: 14.04%
• 10Y*: 9.84%

*Multi-year figures are annualized to reflect compound growth (CAGR)

MRC vs. NVS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
MRC MRC Global Inc.	0.00%	7.82%	16.08%	-4.92%	68.31%	3.77%	-51.39%	11.53%	-27.72%	-16.49%
NVS Novartis AG	7.37%	46.95%	0.02%	16.14%	8.06%	-3.65%	3.34%	13.92%	5.95%	19.42%

Correlation

The correlation between MRC and NVS is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.06
Correlation (3Y) Calculated over the trailing 3-year period	0.07
Correlation (5Y) Calculated over the trailing 5-year period	0.14
Correlation (10Y) Calculated over the trailing 10-year period	0.17
Correlation (All Time) Calculated using the full available price history since Apr 13, 2012	0.19

The correlation between MRC and NVS shifts across timeframes, from 0.06 (1 year) to 0.19 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap MRC : $1.16B NVS : $275.25B
EPS MRC : -$0.48 NVS : $6.99
PS Ratio MRC : 0.43 NVS : 4.96
PB Ratio MRC : 2.19 NVS : 7.15
Total Revenue (TTM) MRC : $2.76B NVS : $56.05B
Gross Profit (TTM) MRC : $542.00M NVS : $42.19B
EBITDA (TTM) MRC : $93.00M NVS : $22.40B

Return for Risk

MRC vs. NVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVS

NVS Risk / Return Rank: 75
NVS Sharpe Ratio Rank: 79
NVS Sortino Ratio Rank: 73
NVS Omega Ratio Rank: 71
NVS Calmar Ratio Rank: 76
NVS Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MRC vs. NVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MRC Global Inc. (MRC) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	MRC	NVS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.37	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.75	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.50	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.42	—

Drawdowns

Drawdown Indicators

	MRC	NVS	Difference
Max Drawdown Largest peak-to-trough decline	—	-42.10%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-12.65%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-19.95%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-20.42%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-26.03%	—
Current Drawdown Current decline from peak	—	-12.21%	—
Average Drawdown Average peak-to-trough decline	—	-10.93%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	5.03%	—

Volatility

Volatility by Period

	MRC	NVS	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	5.62%	—
Volatility (6M) Calculated over the trailing 6-month period	—	14.25%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	20.28%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	18.78%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	19.59%	—

Dividends

MRC vs. NVS - Dividend Comparison

MRC has not paid dividends to shareholders, while NVS's dividend yield for the trailing twelve months is around 3.32%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
MRC MRC Global Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVS Novartis AG	3.32%	2.90%	3.84%	3.44%	3.70%	3.86%	3.22%	3.03%	3.47%	3.24%	3.73%	3.10%

Financials

MRC vs. NVS - Profitability Comparison

The chart below illustrates the profitability comparison between MRC Global Inc. and Novartis AG over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

MRC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, MRC Global Inc. reported a gross profit of 125.00M and revenue of 678.00M. Therefore, the gross margin over that period was 18.4%.

NVS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.

MRC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, MRC Global Inc. reported an operating income of -3.00M and revenue of 678.00M, resulting in an operating margin of -0.4%.

NVS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.

MRC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, MRC Global Inc. reported a net income of -9.00M and revenue of 678.00M, resulting in a net margin of -1.3%.

NVS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.

Frequently Asked Questions

Can I hold both MRC and NVS in my portfolio?

MRC and NVS have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.